These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

524 related articles for article (PubMed ID: 22731961)

  • 21. The role of glutamate on the action of antidepressants.
    Hashimoto K
    Prog Neuropsychopharmacol Biol Psychiatry; 2011 Aug; 35(7):1558-68. PubMed ID: 20600468
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The role of NMDA receptors in the pathophysiology and treatment of mood disorders.
    Ghasemi M; Phillips C; Trillo L; De Miguel Z; Das D; Salehi A
    Neurosci Biobehav Rev; 2014 Nov; 47():336-58. PubMed ID: 25218759
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Novel Glutamatergic Modulators for the Treatment of Mood Disorders: Current Status.
    Henter ID; Park LT; Zarate CA
    CNS Drugs; 2021 May; 35(5):527-543. PubMed ID: 33904154
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Targeting glutamate signalling in depression: progress and prospects.
    Murrough JW; Abdallah CG; Mathew SJ
    Nat Rev Drug Discov; 2017 Jul; 16(7):472-486. PubMed ID: 28303025
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Ketamine and Other NMDA Antagonists: Early Clinical Trials and Possible Mechanisms in Depression.
    Newport DJ; Carpenter LL; McDonald WM; Potash JB; Tohen M; Nemeroff CB;
    Am J Psychiatry; 2015 Oct; 172(10):950-66. PubMed ID: 26423481
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Effect of baseline anxious depression on initial and sustained antidepressant response to ketamine.
    Ionescu DF; Luckenbaugh DA; Niciu MJ; Richards EM; Slonena EE; Vande Voort JL; Brutsche NE; Zarate CA
    J Clin Psychiatry; 2014 Sep; 75(9):e932-8. PubMed ID: 25295436
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Ketamine for treatment of acute depression].
    Hjerrild S; Bjerre J; Pedersen RH; Videbech P
    Ugeskr Laeger; 2013 Sep; 175(37):2090-3. PubMed ID: 24011203
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Clinical overview of NMDA-R antagonists and clinical practice.
    Davoudian PA; Wilkinson ST
    Adv Pharmacol; 2020; 89():103-129. PubMed ID: 32616204
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Randomized proof of concept trial of GLYX-13, an N-methyl-D-aspartate receptor glycine site partial agonist, in major depressive disorder nonresponsive to a previous antidepressant agent.
    Preskorn S; Macaluso M; Mehra DO; Zammit G; Moskal JR; Burch RM;
    J Psychiatr Pract; 2015 Mar; 21(2):140-9. PubMed ID: 25782764
    [TBL] [Abstract][Full Text] [Related]  

  • 30. How does ketamine elicit a rapid antidepressant response?
    Kavalali ET; Monteggia LM
    Curr Opin Pharmacol; 2015 Feb; 20():35-9. PubMed ID: 25462290
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Importance of Exploring N-Methyl-D-Aspartate (NMDA) as a Future Perspective Target in Depression.
    Bhatia NY; Ved HS; Kale PP; Doshi GM
    CNS Neurol Disord Drug Targets; 2022; 21(10):1004-1016. PubMed ID: 35352638
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Glutamatergic approaches in major depressive disorder: focus on ketamine, memantine and riluzole.
    Owen RT
    Drugs Today (Barc); 2012 Jul; 48(7):469-78. PubMed ID: 22844658
    [TBL] [Abstract][Full Text] [Related]  

  • 33. New Treatment Strategies of Depression: Based on Mechanisms Related to Neuroplasticity.
    Huang YJ; Lane HY; Lin CH
    Neural Plast; 2017; 2017():4605971. PubMed ID: 28491480
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The rapid-onset antidepressant effect of ketamine: More surprises?
    Raffa RB; Pergolizzi JV; Taylor R;
    J Clin Pharm Ther; 2018 Apr; 43(2):308-311. PubMed ID: 29178131
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Glutamate and Gamma-Aminobutyric Acid Systems in the Pathophysiology of Major Depression and Antidepressant Response to Ketamine.
    Lener MS; Niciu MJ; Ballard ED; Park M; Park LT; Nugent AC; Zarate CA
    Biol Psychiatry; 2017 May; 81(10):886-897. PubMed ID: 27449797
    [TBL] [Abstract][Full Text] [Related]  

  • 36. NMDA antagonists under investigation for the treatment of major depressive disorder.
    Pochwat B; Pałucha-Poniewiera A; Szewczyk B; Pilc A; Nowak G
    Expert Opin Investig Drugs; 2014 Sep; 23(9):1181-92. PubMed ID: 24818801
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Repurposing of Drugs-The Ketamine Story.
    Das J
    J Med Chem; 2020 Nov; 63(22):13514-13525. PubMed ID: 32915563
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Ketamine and rapid-acting antidepressants: a window into a new neurobiology for mood disorder therapeutics.
    Abdallah CG; Sanacora G; Duman RS; Krystal JH
    Annu Rev Med; 2015; 66():509-23. PubMed ID: 25341010
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Zinc in the Glutamatergic Theory of Depression.
    Mlyniec K
    Curr Neuropharmacol; 2015; 13(4):505-13. PubMed ID: 26412070
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Therapeutic Modulation of Glutamate Receptors in Major Depressive Disorder.
    Jaso BA; Niciu MJ; Iadarola ND; Lally N; Richards EM; Park M; Ballard ED; Nugent AC; Machado-Vieira R; Zarate CA
    Curr Neuropharmacol; 2017; 15(1):57-70. PubMed ID: 26997505
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 27.